 NCCN guideline of 2015 recommended that patients with esophageal squamous cell carcinoma in T1b, N and T2-T4a, N0-N may consider preoperative neoadjuvant therapy, but its supporting literature David Cunningham 2006, Marc Ychou 2011 and P. van Hagen, 2013 includes patients with pathology of the type adenocarcinoma. The esophageal cancer treatment guidelines of Japan 2015 adopted the opinion of NCCN Guidelines, and recommended neoadjuvant chemotherapy and radical surgery as the standard treatment for stage II and III esophageal cancer patients based on the results of randomized controlled clinical trial JCOG9907. However, the guidelines also pointed out that the role of neoadjuvant chemotherapy for resectable T1-3N0-1M0 cancers remains unclear according to the results of some meta-analysis. But at least for the present studies, compared to direct surgery group, the patients received neoadjuvant therapy did not show inferior effect at aspects such as radical surgery, postoperative complications, disease-free survival and overall survival. 